@
Richard14 If administered within five days of symptom onset, the efficacy of the co-packaged medication against hospitalization or death in unvaccinated high-risk adults is about 88% (95% CI, 75–94%).[11][20]
11 Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid (PDF) (Technical report). Pfizer. 22 December 2021. LAB-1492-0.8. Archived from the original on 23 December 2021.
20 ^ Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. (April 2022). "Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19". The New England Journal of Medicine. 386 (15): 1397–1408.